↓ Skip to main content

Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study

Overview of attention for article published in Gastric Cancer, August 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#30 of 623)
  • High Attention Score compared to outputs of the same age (85th percentile)
  • High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

twitter
2 X users
patent
4 patents

Citations

dimensions_citation
10 Dimensions

Readers on

mendeley
27 Mendeley
Title
Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study
Published in
Gastric Cancer, August 2015
DOI 10.1007/s10120-015-0536-6
Pubmed ID
Authors

Eisuke Booka, Chiyo K. Imamura, Hiroya Takeuchi, Yasuo Hamamoto, Daisuke Gomi, Takuro Mizukami, Takashi Ichiyama, Kazunari Tateishi, Tsunehiro Takahashi, Hirofumi Kawakubo, Kenzo Soejima, Narikazu Boku, Yusuke Tanigawara, Yuko Kitagawa

Abstract

S-1 is an oral anticancer drug, containing tegafur (a prodrug of 5-fluorouracil, 5-FU), 5-chloro-2,4-dihydroxypyridine, and potassium oxonate. As renal dysfunction is known to increase exposure of 5-FU following S-1 administration, the incidence of severe adverse reactions is increased in patients with impaired renal function. However, no reliable information on its dose modification for patients with renal dysfunction has been provided. We conducted a prospective pharmacokinetic study to develop an S-1 dosage formula based on renal function. Sixteen cancer patients with various degrees of renal function received a single dose of S-1 at 40 mg/m(2). A series of blood samples were collected at predefined times within 24 h to assess the plasma concentration profiles of 5-FU, 5-chloro-2,4-dihydroxypyridine, and tegafur. A mathematical model for the relationship between renal function and exposure of 5-FU was constructed by a population pharmacokinetic analysis. The clearance of 5-FU following S-1 administration was related to body surface area and creatinine clearance in the range 15.9-108.8 mL/min as estimated by the Cockcroft-Gault equation. The S-1 dosage formula was derived as follows:[Formula: see text]where AUC is the area under the concentration-time curve, CLcr is creatinine clearance, and BSA is body surface area. The recommended daily doses of S-1 in Asia and Europe were also proposed as nomograms according to exposure matching to the previously reported area under the concentration-time curve of 5-FU, which confirmed the efficacy and toxicity in pivotal registration studies. We have developed a novel formula for determining the S-1 dosage on the basis of renal function. Further validation is needed to confirm the formula for practical application.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 27 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 22%
Student > Ph. D. Student 4 15%
Lecturer 2 7%
Student > Bachelor 2 7%
Professor > Associate Professor 2 7%
Other 4 15%
Unknown 7 26%
Readers by discipline Count As %
Medicine and Dentistry 11 41%
Unspecified 1 4%
Biochemistry, Genetics and Molecular Biology 1 4%
Pharmacology, Toxicology and Pharmaceutical Science 1 4%
Psychology 1 4%
Other 1 4%
Unknown 11 41%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 October 2022.
All research outputs
#3,175,524
of 24,849,927 outputs
Outputs from Gastric Cancer
#30
of 623 outputs
Outputs of similar age
#40,166
of 273,270 outputs
Outputs of similar age from Gastric Cancer
#2
of 18 outputs
Altmetric has tracked 24,849,927 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 623 research outputs from this source. They receive a mean Attention Score of 3.1. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 273,270 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.